Staidson Beijing Biopharma

SHE:300204 China Biotechnology

Market Cap

$1.64 Billion

CN¥12.02 Billion CNY

Market Cap Rank

#7564 Global

#1305 in China

Share Price

CN¥25.15

Change (1 day)

-1.30%

52-Week Range

CN¥6.27 - CN¥61.00

All Time High

CN¥61.00

Staidson Beijing Biopharma - Asset Resilience Ratio

Latest as of September 2022: 7.93%

Staidson Beijing Biopharma (300204) has an Asset Resilience Ratio of 7.93% as of September 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥130.40 Million

Cash + Short-term Investments

Total Assets

CN¥1.64 Billion

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2021)

This chart shows how Staidson Beijing Biopharma's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Staidson Beijing Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥130.40 Million	7.93%
Total Liquid Assets	CN¥130.40 Million	7.93%

Asset Resilience Insights

Limited Liquidity: Staidson Beijing Biopharma maintains only 7.93% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.